ITEM METADATA RECORD
Title: Fulvestrant (Faslodex trademark) in advanced breast cancer: clinical experience from a Belgian cooperative study
Authors: Neven, Patrick ×
Paridaens, Robert
Pelgrims, Gino
Martens, Marc
Bols, Alain
Goeminne, Jean Charles
Vindevoghel, Anita
Demol, Jan
Stragier, Barbara
De Greve, Jacques
Fontaine, Christel
Van Den Weyngaert, Danielle
Becquart, Dominique
Borms, Marleen
Cocquyt, Veronique
Van Den Broecke, Rudy
Selleslags, Jean
Awada, Ahmad
Dirix, Luc
Van Dam, Peter
Azerad, Marie Agnes
Vandenhoven, Guy
Christiaens, Marie-Rose
Vergote, Ignace #
Issue Date: May-2008
Publisher: M. Nijhoff
Series Title: Breast Cancer Research and Treatment vol:109 issue:1 pages:59-65
Abstract: Fulvestrant (Faslodextrade mark) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The Faslodextrade mark Compassionate Use Program (CUP) provides expanded access to fulvestrant in countries where it is not yet available for patients who are not eligible to enter clinical trials. This analysis pools data from 402 patients who received fulvestrant as part of the CUP in Belgium, predominantly as 3rd- to 5th-line endocrine therapy for ABC. Two patients experienced partial responses and 118 experienced stable disease lasting >/=6 months, resulting in an overall clinical benefit rate of 29.9%. Fulvestrant was active in patients with multiple sites of metastases, visceral metastases, human epidermal growth factor receptor 2-positive disease and after heavy endocrine pre-treatment. Fulvestrant was well tolerated, with only six patients (1.5%) discontinuing treatment following adverse events. These data support the findings of previous CUP analyses and Phase II and III trials, suggesting that fulvestrant is a valuable addition to the treatment sequence for postmenopausal women with ABC who have progressed/recurred on prior endocrine therapy.
URI: 
ISSN: 0167-6806
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
Multidisciplinary Breast Clinic Section (-)
Gynaecological Oncology
Surgical Oncology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Fulvestrant (Faslodextrade mark) in advanced breast cancer clinical experience from a Belgian cooperative study.pdf Published 222KbAdobe PDFView/Open

 


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science